Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Cardinal’s Dik Acquisition Aims To Grow Independent Pharmacy Ties, Generic Rx Sales

This article was originally published in The Pink Sheet Daily

  • News

Executive Summary

Cardinal agrees to purchase regional distributor Dik Drug, bringing in business with about 500 independent retail pharmacies and high generic drug volume.

You may also be interested in...



Cardinal’s China Operations Running “Ahead Of Plan,” More Expansion Ahead

Cardinal Health Boosts Generics Wholesale Business With $1.3 Billion Kinray Acquisition

Acquisition widens Cardinal's presence in New York metro area and boosts business with independent retail pharmacies 40%.

GSK's Nucala Is Significantly Overpriced, ICER Draft Report Finds

New biologic for severe asthma doesn't stack up well to standard of care on generally accepted levels of cost per quality-adjusted life year.

Table

View full table

Related Companies

Tags:
Latest Headlines

Partisan Politics Returns To US FDA Congressional Oversight

GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows

Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development

EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications

See All
UsernamePublicRestriction

Register

PS074122

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By